{
  "abstract": "A 10-month-old girl with genetically confirmed spinal muscular atrophy (SMA) (homozygous deletion of SMN1 exon 7) was identified through newborn screening. By 9 months, she could sit with support and had preserved hand function. She had received five doses of nusinersen before consideration of onasemnogene abeparvovec (OA), an adeno-associated virus-based gene replacement therapy.",
  "authors": [
    {
      "affiliations": [
        "Paediatric Neurology, Aster DM Healthcare, Dubai, UAE"
      ],
      "name": "Vivek Mundada"
    }
  ],
  "title": "Foot that spoke first: microvascular signs of a motor neuron disease",
  "uid": "4bbb3a7e-b6f1-54ab-85bc-254ccf8addfe"
}